다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Journal of the American College of Cardiology, v.67 no.16, 2016년, pp.1941 - 1955
Becattini, C. , Agnelli, G.
AI-Helper
Venous thromboembolism (VTE) is a common disease associated with high risk for recurrences, death, and late sequelae, accounting for substantial health care costs. Anticoagulant agents are the mainstay of treatment for deep vein thrombosis and pulmonary embolism. The recent availability of oral anti...
Thromb Haemost Martinez 112 255 2014 10.1160/TH13-09-0793 Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer
Am J Med Tagalakis 126 832.e13 2013 10.1016/j.amjmed.2013.02.024 Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort
Arch Intern Med Wiener 171 831 2011 Time trends in pulmonary embolism in the United States: evidence of overdiagnosis
Thromb Res 134 931 2014 10.1016/j.thromres.2014.08.014 Thrombosis: a major contributor to global disease burden
Thromb Haemost Cohen 98 756 2007 10.1160/TH07-03-0212 Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality
Clin Appl Thromb Hemost Yusuf 20 136 2014 10.1177/1076029613493659 Hospitalizations of adults ≥60 years of age with venous thromboembolism
Vasc Med Kroger 17 303 2012 10.1177/1358863X12449363 Prevalence and economic burden of pulmonary embolism in Germany
Clin Ther LaMori 37 62 2015 10.1016/j.clinthera.2014.10.024 Inpatient resource use and cost burden of deep vein thrombosis and pulmonary embolism in the United States
Circulation Søgaard 130 829 2014 10.1161/CIRCULATIONAHA.114.009107 30-Year mortality after venous thromboembolism: a population-based cohort study
BMJ Boutitie 342 d3036 2011 10.1136/bmj.d3036 Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials
Ann Intern Med Agnelli 139 19 2003 10.7326/0003-4819-139-1-200307010-00008 Extended oral anticoagulant therapy after a first episode of pulmonary embolism
Circulation Lang 130 508 2014 10.1161/CIRCULATIONAHA.114.009309 Update on chronic thromboembolic pulmonary hypertension
N Engl J Med Pengo 350 2257 2004 10.1056/NEJMoa032274 Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism
Ann Intern Med Kahn 149 698 2008 10.7326/0003-4819-149-10-200811180-00004 Determinants and time course of the post-thrombotic syndrome after acute deep venous thrombosis
Arch Intern Med Ginsberg 161 2105 2001 10.1001/archinte.161.17.2105 Prevention and treatment of postphlebitic syndrome: results of a 3-part study
J Vasc Surg Aschwanden 47 1015 2008 10.1016/j.jvs.2008.01.008 Effect of prolonged treatment with compression stockings to prevent post-thrombotic sequelae: a randomized controlled trial
Circulation Kahn 130 1636 2014 10.1161/CIR.0000000000000130 The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association
Am J Health Syst Pharm MacDougall 63 20 Suppl 6 S5 2006 10.2146/ajhp060388 Economic burden of deep vein thrombosis, pulmonary embolism, and post-thrombotic syndrome
BMC Health Serv Res Schweikert 14 246 2014 10.1186/1472-6963-14-246 Demographics, clinical characteristics, health resource utilization and cost of chronic thromboembolic pulmonary hypertension patients: retrospective results from six European countries
Chest Kearon 141 e419S 2012 10.1378/chest.11-2301 Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-based Clinical Practice Guidelines
Eur Respir J Agnelli 45 1142 2015 10.1183/09031936.00164714 Anticoagulant treatment for acute pulmonary embolism: a pathophysiology-based clinical approach
Arch Intern Med Anand 159 2029 1999 10.1001/archinte.159.17.2029 Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times
JAMA Fiessinger 293 681 2005 10.1001/jama.293.6.681 Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial
N Engl J Med 357 1094 2007 10.1056/NEJMoa064247 Idraparinux versus standard therapy for venous thromboembolic disease
J Thromb Haemost Nieto 8 1216 2010 10.1111/j.1538-7836.2010.03852.x Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry
Thromb Haemost Lecumberri 110 834 2013 10.1160/TH13-02-0132 Dynamics of case-fatality rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism
Ann Intern Med Prandoni 125 1 1996 10.7326/0003-4819-125-1-199607010-00001 The long-term clinical course of acute deep venous thrombosis
Lancet Baglin 362 523 2003 10.1016/S0140-6736(03)14111-6 Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study
Arch Intern Med Iorio 170 1710 2010 10.1001/archinternmed.2010.367 Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review
N Engl J Med Agnelli 345 165 2001 10.1056/NEJM200107193450302 Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis
Eur Heart J Konstantinides 35 3033 2014 10.1093/eurheartj/ehu283 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism
Pharmacotherapy Baetz 28 1354 2008 10.1592/phco.28.11.1354 Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases
Clin Pharmacol Ther Kubitza 78 412 2005 10.1016/j.clpt.2005.06.011 Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
Drug Metab Dispos Raghavan 37 74 2009 10.1124/dmd.108.023143 Apixaban metabolism and pharmacokinetics after oral administration to humans
Hamostaseologie Ahrens 32 212 2012 10.5482/HAMO-12-05-0004 Oral anticoagulation with edoxaban. Focus on current phase III clinical development
Europace Heidbuchel 17 1467 2015 10.1093/europace/euv309 Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation
N Engl J Med Schulman 361 2342 2009 10.1056/NEJMoa0906598 Dabigatran versus warfarin in the treatment of acute venous thromboembolism
Circulation Schulman 129 764 2014 10.1161/CIRCULATIONAHA.113.004450 Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis
N Engl J Med 363 2499 2010 10.1056/NEJMoa1007903 Oral rivaroxaban for symptomatic venous thromboembolism
N Engl J Med 366 1287 2012 10.1056/NEJMoa1113572 Oral rivaroxaban for the treatment of symptomatic pulmonary embolism
N Engl J Med Agnelli 369 799 2013 10.1056/NEJMoa1302507 Oral apixaban for the treatment of acute venous thromboembolism
N Engl J Med 369 1406 2013 10.1056/NEJMoa1306638 Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism
Thromb J Prins 11 21 2013 10.1186/1477-9560-11-21 Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies
J Cardiovasc Pharmacol Ther Gomez-Outes 20 490 2015 10.1177/1074248415575154 Case fatality rates of recurrent thromboembolism and bleeding in patients receiving direct oral anticoagulants for the initial and extended treatment of venous thromboembolism: a systematic review
Eur J Vasc Endovasc Surg Kakkos 48 565 2014 10.1016/j.ejvs.2014.05.001 Editor's choice-efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials
Int J Cardiol Vedovati 177 601 2014 10.1016/j.ijcard.2014.08.136 Efficacy and safety of direct oral anticoagulants after pulmonary embolism: a meta-analysis
Intern Emerg Med Dentali 10 507 2015 10.1007/s11739-015-1249-x Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature
J Thromb Thrombolysis Mantha 39 155 2015 10.1007/s11239-014-1102-5 Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism
Blood van Es 124 1968 2014 10.1182/blood-2014-04-571232 Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials
Thromb J Bauersachs 12 25 2014 10.1186/1477-9560-12-25 Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment
J Thromb Haemost Prins 13 35 2015 AS099: fixed-dose rivaroxaban is not associated with increased recurrent venous thromboembolism or major bleeding in patients with a high or low body weight
JAMA Intern Med Davidson 174 947 2014 10.1001/jamainternmed.2014.946 Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin
Blood Schulman 122 1136 2013 10.1182/blood.V122.21.1136.1136 Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-COVER and RE-COVER II
Blood Schulman 124 1544 2014 10.1182/blood.V124.21.1544.1544 Influence of thrombophilia on the efficacy of dabigatran versus warfarin for the extended treatment of acute venous thromboembolism in RE-MEDY
Chest Vedovati 147 475 2015 10.1378/chest.14-0402 Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis
Lancet Goldhaber 353 1386 1999 10.1016/S0140-6736(98)07534-5 Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER)
Arch Intern Med Jimenez 170 1383 2010 10.1001/archinternmed.2010.199 Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism
Crit Care Coutance 15 R103 2011 10.1186/cc10119 The prognostic value of markers of right ventricular dysfunction in pulmonary embolism: a meta-analysis
Eur Respir J Becattini 43 1678 2014 10.1183/09031936.00147813 Computed tomography to assess risk of death in acute pulmonary embolism: a meta-analysis
Circulation Becattini 116 427 2007 10.1161/CIRCULATIONAHA.106.680421 Prognostic value of troponins in acute pulmonary embolism: a meta-analysis
JAMA Chatterjee 311 2414 2014 10.1001/jama.2014.5990 Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis
N Engl J Med Meyer 370 1402 2014 10.1056/NEJMoa1302097 Fibrinolysis for patients with intermediate-risk pulmonary embolism
Clin Cardiol Sharifi 37 78 2014 10.1002/clc.22216 Safe-dose thrombolysis plus rivaroxaban for moderate and severe pulmonary embolism: drip, drug, and discharge
J Thromb Haemost Vedovati 11 2092 2013 10.1111/jth.12429 Prognostic role of embolic burden assessed at computed tomography angiography in patients with acute pulmonary embolism: systematic review and meta-analysis
Acad Emerg Med Fermann 22 299 2015 10.1111/acem.12615 Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified pulmonary embolism severity index score from a post hoc analysis of the EINSTEIN PE study
Lancet Aujesky 378 41 2011 10.1016/S0140-6736(11)60824-6 Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial
J Thromb Haemost den Exter 13 193 2015 OR257: Efficacy and safety of outpatient treatment based on the Hestia clinical decision rule with or without NT-proBNP testing in patients with acute pulmonary embolism: a randomized trial
J Thromb Haemost Scherz 11 435 2013 10.1111/jth.12111 Prospective, multicenter validation of prediction scores for major bleeding in elderly patients with venous thromboembolism
Thromb Haemost Riva 112 511 2014 10.1160/TH14-01-0081 Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism. A multicentre retrospective cohort study
Thromb Res Dentali 125 518 2010 10.1016/j.thromres.2010.03.016 Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis
Curr Med Res Opin van Bellen 30 829 2014 10.1185/03007995.2013.879439 Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism
Chest Horner 146 1468 2014 10.1378/chest.14-0235 The anticoagulation of calf thrombosis (ACT) project: results from the randomized controlled external pilot trial
Circulation Pinede 103 2453 2001 10.1161/01.CIR.103.20.2453 Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis
J Thromb Haemost Righini 13 50 2015 AS137: anticoagulant therapy for symptomatic distal deep vein thrombosis: the CACTUS randomized placebo controlled trial (abstr)
J Thromb Haemost Levi 9 1705 2011 10.1111/j.1538-7836.2011.04432.x Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents
Med J Aust Baker 181 492 2004 10.5694/j.1326-5377.2004.tb06407.x Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis
Thromb Res Voils 130 833 2012 10.1016/j.thromres.2012.10.001 Systematic review: 3-factor versus 4-factor prothrombin complex concentrate for warfarin reversal: does it matter?
Circulation Eerenberg 124 1573 2011 10.1161/CIRCULATIONAHA.111.029017 Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects
Blood Glund 124 344 2014 10.1182/blood.V124.21.344.344 Idarucizumab, a specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in elderly and renally impaired subjects (abstr)
Lancet Glund 386 680 2015 10.1016/S0140-6736(15)60732-2 Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial
N Engl J Med Pollack 373 511 2015 10.1056/NEJMoa1502000 Idarucizumab for dabigatran reversal
J Thromb Haemost Crowther 11 30 2013 AS20.1: a phase 2 randomized, double-blind, placebo-controlled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors
Eur Heart J Crowther 35 137 2014 P738: sustained reversal of apixaban anticoagulation with andexanet alfa using a bolus plus infusion regimen in a phase 2 placebo controlled trial (abstr)
N Engl J Med Siegal 373 2413 2015 10.1056/NEJMoa1510991 Andexanet alfa for the reversal of factor Xa inhibitor activity
N Engl J Med Ansell 371 2141 2014 10.1056/NEJMc1411800 Use of PER977 to reverse the anticoagulant effect of edoxaban
N Engl J Med Schulman 368 709 2013 10.1056/NEJMoa1113697 Extended use of dabigatran, warfarin, or placebo in venous thromboembolism
N Engl J Med Agnelli 368 699 2012 10.1056/NEJMoa1207541 Apixaban for extended treatment of venous thromboembolism
Thromb Haemost Weitz 114 645 2015 10.1160/TH15-02-0131 Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study
J Med Econ Amin 17 763 2014 Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients
Eur Heart J Agnelli 35 1002 2014 P5559: the current use of direct oral anticoagulants (DOACs) for the treatment of VTE in Europe-PREFER in VTE (abstr)
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
저자가 APC(Article Processing Charge)를 지불한 논문에 한하여 자유로운 이용이 가능한, hybrid 저널에 출판된 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.